A Safety, Tolerability and Pharmacokinetic Study of CPP-115
A Phase 1, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of CPP-115 Solution Administered Orally to Healthy Volunteers
Sponsor: Catalyst Pharmaceuticals, Inc.
A PHASE1 clinical study on Cocaine Dependency, this trial is completed. The trial is conducted by Catalyst Pharmaceuticals, Inc. and has accumulated 9 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
May 2021 — Dec 2022 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Jan 2021 — May 2021 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Catalyst Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .